Lawmakers agree on $10 billion additional funding for U.S. COVID response (Updated)
uschools/E+ via Getty Images

Update: Congressional leaders announced on Monday an agreement for a scaled-back legislation to secure $10 billion in additional funding for U.S. COVID-19 response, New York Daily News reported.
According to a fact sheet distributed by Sen. Mitt Romney (R-Utah), at least half of the measure is earmarked for R&D efforts targeting treatments, and at least $750 million would be allocated for research on new COVID-19 variants and to increase vaccine production.
A Democrat of the House Progressive Caucus doubted if the new piece of legislation would garner the minimum 10 GOP votes to advance through the Senate. However, others said that sufficient Republican votes would be there for its passage. 
Previously: Congressional negotiators have agreed on a $10 billion additional funding for U.S. COVID-19 response, and the deal is expected to be announced on Monday, The Washington Post reported citing two people with knowledge of the matter. 
The package provides funds for the purchase of more therapeutics, tests, vaccines, and other supplies. 
However, the lawmakers have failed to reach an agreement for a $15 billion package that included $5 billion for the global response which President Biden previously said was critical to keep Americans safe from the threat of new variants.
Developers of COVID-19 antibody therapies: Gilead (GILD), Eli Lilly (LLY), Vir Biotechnology (VIR)/ GlaxoSmithKline (GSK), Regeneron (REGN).
The makers of COVID-19 pills: Pfizer (PFE), Merck (MRK).
COVID-19 vaccine makers: Pfizer (PFE)/ BioNTech (BNTX), Moderna (MRNA), Johnson & Johnson (JNJ)
Last month, the Biden administration warned that the government was at risk of running out of COVID-19 antibody therapies as early as May unless Congress clears additional funds.